NOVELTY - An intraocular implant system comprises: an implant sized and adapted for intraocular placement and comprising a therapeutic component associated with a biodegradable polymer, the implant is structured to release the therapeutic component discontinuously or intermittently over time after intraocular implantation of the implant.    USE - For treating an ocular condition (claimed) such as maculopathies, retinal degeneration, uveitis, retinitis, choroiditis, vascular diseases, exudative diseases, proliferative disorders, infectious disorders, genetic disorders, tumors, trauma, and surgery, retinal tears or holes, aphakia, pseudophakia, astigmatism, blepharospasm, cataract, conjunctival diseases, corneal diseases, corneal ulcer, dry eye syndromes, eyelid diseases, lacrimal apparatus diseases, lacrimal duct obstruction, myopia, presbyopia, pupil disorders, refractive disorders and strabismus, glaucoma, posterior ocular condition such as acute macular neuroretinopathy; Behcet's disease; choroidal neovascularization; diabetic uveitis; histoplasmosis; fungal or viral-caused infections; edema, such as macular edema, cystoid macular edema and diabetic macular edema; multifocal choroiditis; retinal disorders, such as central retinal vein occlusion, diabetic retinopathy (including proliferative diabetic retinopathy), proliferative vitreoretinopathy (PVR), retinal arterial occlusive disease, retinal detachment, uveitic retinal disease; sympathetic opthalmia; Vogt Koyanagi-Harada (VKH) syndrome; uveal diffusion; posterior ocular conditions caused by or influenced by a photodynamic therapy, photocoagulation, radiation retinopathy, epiretinal membrane disorders, branch retinal vein occlusion, anterior ischemic optic neuropathy, non-retinopathy diabetic retinal dysfunction and retinitis pigmentosa.    ADVANTAGE - The implants exhibit a cumulative release profile that may have a shallower slope, or a lower rate of release, for longer periods of time than existing implants. The implants release an active agent into the interior of the eye in an amount having a reduced toxicity relative to bolus or liquid injections of the same agent without a polymeric component and provide prolonged therapeutic effects without requiring large doses. The steroid is gradually released over time without causing ocular toxicity or other adverse side effects that are associated with injection of the steroid in a liquid formulation. The steroid can be alternated within different shells of the implant such that it is delivered only over particular time periods, with time periods of (or no) steroid being delivered intervening. In this way continued exposure of the eye to the steroid, and the side effects that may accompany such constant delivery, may be avoided or reduced. The first and second implants is structured to release the therapeutic component so that during at least one periods of time after implantation in an eye the intraocular concentration of the therapeutic component is reduced sufficiently to decrease the risk of an adverse side effect of the therapeutic component relative to maintaining a higher intraocular concentration of the therapeutic component during the at least one period of time after intraocular placement. The auxiliary agent is selected to be effective to reduce the risk of an adverse side effect (glaucoma) of the therapeutic component in an eye.    DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for method for treating an ocular condition, involving: (a) intravitreal placement of a biodegradable implant which comprises a therapeutic component, and; (b) pulsatile release of the therapeutic component from the implant into the vitreous, thereby treating the ocular condition.